ProMIS Neurosciences secures $20M+ PIPE; Beam Therapeutics reveals data ahead of IND

ProMIS Neu­ro­sciences, a biotech fo­cused on de­vel­op­ing treat­ments for neu­rode­gen­er­a­tive dis­eases, closed a pri­vate in­vest­ment in pub­lic eq­ui­ty, or PIPE, that brought in $20.4 mil­lion.

The fund­ing is set to go to­ward de­vel­op­ing ProMIS’ lead can­di­date, PMN310, a pre­clin­i­cal an­ti-amy­loid ther­a­py de­signed to treat Alzheimer’s dis­ease, ac­cord­ing to a news re­lease on Fri­day. — Tyler Patchen

Beam shares pre­clin­i­cal da­ta on AATD base edit­ing treat­ment ahead of IND

Beam Ther­a­peu­tics said Thurs­day that its base edit­ing treat­ment for al­pha-1 an­tit­rypsin de­fi­cien­cy, or AATD, helped in­crease lev­els of a func­tion­al pro­tein in rats and mice and de­crease lev­els of a mu­tat­ed pro­tein.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.